<DOC>
	<DOC>NCT01071252</DOC>
	<brief_summary>The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).</brief_summary>
	<brief_title>A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Chronic plaquetype psoriasis diagnosed for at least 6 months at time of randomization At randomization, moderate to severe psoriasis as defined by: PASI score of 12 or greater and, IGA score of 3 or greater and, Body Surface Area (BSA) affected by plaquetype psoriasis of 10% or greater At screening and randomization, chronic plaquetype psoriasis considered inadequately controlled by topical treatment. Forms of psoriasis other than chronic plaquetype Druginduced psoriasis (e.g., new onset or current exacerbation from betablockers, calcium channel inhibitors or lithium) at randomization Previous exposure to AIN457 Ongoing use of prohibited psoriasis treatments / medications and other prohibited medication at randomization. Washout periods detailed in the protocol have to be adhered to Known immunosuppression (e.g., AIDS) at screening and / or randomization History or evidence of active tuberculosis at screening Active systemic infections (other than common cold) History or symptoms of malignancy of any organ system, treated or untreated, within the past 5 years. Any severe, progressive or uncontrolled medical condition at randomization that in the judgment of the investigator prevents the patient from participating in the study Any clinically significant abnormal laboratory tests at randomization, that in the judgment of the investigator prevents the patient from participating in the study Inability or unwillingness to undergo repeated venipuntures History or evidence of drug or alcohol abuse Pregnant or nursing (lactating) women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Moderate to severe chronic plaque-type psoriasis</keyword>
	<keyword>AIN457</keyword>
	<keyword>dermatology</keyword>
</DOC>